Pulmonx (LUNG) Cash from Operations (2019 - 2025)

Pulmonx (LUNG) has reported Cash from Operations for 7 consecutive years, with -$8.2 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Cash from Operations fell 13.36% year-over-year to -$8.2 million in Q3 2025; TTM through Sep 2025 was -$32.0 million, a 3.57% increase from a year earlier, with the FY2024 full-year figure at -$31.5 million, up 16.15% from the prior year.
• Cash from Operations was -$8.2 million for Q3 2025 at Pulmonx, down from -$3.9 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$3.9 million in Q2 2025 and troughed at -$15.0 million in Q1 2022.
• A 5-year average of -$9.5 million and a median of -$9.6 million in 2022 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations sank 65.09% in 2021 and soared 32.62% in 2025, its largest moves.
• Over 5 years, Cash from Operations stood at -$10.7 million in 2021, then climbed by 8.41% to -$9.8 million in 2022, then advanced by 14.18% to -$8.4 million in 2023, then advanced by 19.98% to -$6.7 million in 2024, then decreased by 21.4% to -$8.2 million in 2025.
• The last three Cash from Operations figures came in at -$8.2 million (Q3 2025), -$3.9 million (Q2 2025), and -$13.2 million (Q1 2025), per Business Quant data.